Cat. No.: HY-30151

Methoxsalen

(Synonyms: 8-Methoxypsoralen; Xanthotoxin; 8-MOP)

17 Cited Publications

Avis client

Based on 17 publication(s) in Google Scholar

Methoxsalen (8-Methoxypsoralen) is a furanocoumarin compound used in psoralen, used in studies of psoriasis, eczema, vitiligo and some sun-exposed cutaneous lymphomas, and is a P450 inhibitor.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.97%
CAS No.: 298-81-7
Formule: C₁₂H₈O₄
Masse moléculaire:216.19

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Methoxsalen Chemical Structure

CAS No.: 298-81-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vivo
- Essai clinique
Chemical Information
Publications (17)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Methoxsalen (8-Methoxypsoralen) is a furanocoumarin compound used in psoralen, used in studies of psoriasis, eczema, vitiligo and some sun-exposed cutaneous lymphomas, and is a P450 inhibitor.

Voir tous les produits spécifiques à Isoform Cytochrome P450 :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	>30 μM Compound: 8-MOP	Antiproliferative activity against human A431 cells after 24 hrs by trypan blue dye assay Antiproliferative activity against human A431 cells after 24 hrs by trypan blue dye assay	[PMID: 22537681]
A-431	IC₅₀	2.48 μM Compound: 8-MOP	Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound	[PMID: 8893844]
A-431	IC₅₀	25 μM Compound: 8-MOP	Antiproliferative activity against human A431 cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay Antiproliferative activity against human A431 cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay	[PMID: 22537681]
AGS	IC₅₀	>100 μM Compound: Xanthotoxin	Anti-proliferative activity against human AGS cells after 48 hrs by MTT assay Anti-proliferative activity against human AGS cells after 48 hrs by MTT assay	[PMID: 28947149]
HCT-116	IC₅₀	>100 μM Compound: 6	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 23746477]
HeLa	IC₅₀	>20 μM Compound: 8 -MOP	Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) in dark condition Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) in dark condition	[PMID: 12930143]
HeLa	IC₅₀	>20 μM Compound: 8-MOP	The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark	[PMID: 10543884]
HeLa	IC₅₀	>20 μM Compound: 8-MOP	Antiproliferative activity against HeLa cells in dark Antiproliferative activity against HeLa cells in dark	[PMID: 16821791]
HeLa	IC₅₀	>20 μM Compound: 8-MOP	Photo-antiproliferative activity against human HeLa cells under dark condition Photo-antiproliferative activity against human HeLa cells under dark condition	[PMID: 19359172]
HeLa	IC₅₀	>30 μM Compound: 8-MOP	Antiproliferative activity against human HeLa cells after 24 hrs by trypan blue dye assay Antiproliferative activity against human HeLa cells after 24 hrs by trypan blue dye assay	[PMID: 22537681]
HeLa	IC₅₀	10 μM Compound: 8-MOP	Antiproliferative activity against human HeLa cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay Antiproliferative activity against human HeLa cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay	[PMID: 22537681]
HeLa	IC₅₀	10 mM Compound: 8-MOP (8-Methoxypsoralen)	In vitro antiproliferative activity against human cervix adenocarcinoma (HeLa) cells In vitro antiproliferative activity against human cervix adenocarcinoma (HeLa) cells	[PMID: 10673096]
HeLa	IC₅₀	10 μM Compound: 8 -MOP	Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) after exposure to UV light Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) after exposure to UV light	[PMID: 12930143]
HeLa	IC₅₀	10 μM Compound: 8-MOP	The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated) The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)	[PMID: 10543884]
HeLa	IC₅₀	10 μM Compound: 8-MOP	Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HeLa cell line Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HeLa cell line	[PMID: 11965365]
HeLa	IC₅₀	10 μM Compound: 8-MOP	Antiproliferative activity against HeLa cells in presence of 0.789 J/cm2 UVA light Antiproliferative activity against HeLa cells in presence of 0.789 J/cm2 UVA light	[PMID: 16821791]
HeLa	IC₅₀	10 μM Compound: 8-MOP	Photo-antiproliferative activity against human HeLa cells exposed to 365 nm, 0.793 Jcm'-2 UVA light Photo-antiproliferative activity against human HeLa cells exposed to 365 nm, 0.793 Jcm'-2 UVA light	[PMID: 19359172]
HeLa	IC₅₀	3.16 μM Compound: 8-MOP	Compound was evaluated for cell growth inhibition against HeLa cell line by irradiation in the presence of examined compound Compound was evaluated for cell growth inhibition against HeLa cell line by irradiation in the presence of examined compound	[PMID: 8893844]
HeLa	IC₅₀	7.6 μg/mL Compound: Xanthotoxin	Antitumor activity against human HeLa cells after 72 hrs by MTS assay Antitumor activity against human HeLa cells after 72 hrs by MTS assay	[PMID: 19217697]
HL-60	IC₅₀	>20 μM Compound: 8-MOP	Cytotoxicity against human HL60 cells treated under dark condition after 24 hrs by trypan blue assay Cytotoxicity against human HL60 cells treated under dark condition after 24 hrs by trypan blue assay	[PMID: 20615713]
HL-60	IC₅₀	>20 μM Compound: 8-MOP	Cytotoxicity against human HL60 cells treated under dark condition after 72 hrs by trypan blue assay Cytotoxicity against human HL60 cells treated under dark condition after 72 hrs by trypan blue assay	[PMID: 20615713]
HL-60	IC₅₀	>20 μM Compound: 8 -MOP	Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) in dark condition Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) in dark condition	[PMID: 12930143]
HL-60	IC₅₀	>20 μM Compound: 8-MOP	The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark	[PMID: 10543884]
HL-60	IC₅₀	>20 μM Compound: 8-MOP	Antiproliferative activity against HL60 cells in dark Antiproliferative activity against HL60 cells in dark	[PMID: 16821791]
HL-60	IC₅₀	0.75 μM Compound: 8-MOP	Compound was evaluated for cell growth inhibition against HL 60 cell line by irradiation in the presence of examined compound Compound was evaluated for cell growth inhibition against HL 60 cell line by irradiation in the presence of examined compound	[PMID: 8893844]
HL-60	IC₅₀	1.2 μM Compound: 8-MOP	Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HL-60	IC₅₀	1.2 μM Compound: 8-MOP	Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm2 UVA dose Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm2 UVA dose	[PMID: 15837311]
HL-60	IC₅₀	1.4 μM Compound: 8-MOP	Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HL-60	IC₅₀	1.4 μM Compound: 8-MOP	Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm2 UVA dose Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm2 UVA dose	[PMID: 15837311]
HL-60	IC₅₀	5.4 μM Compound: 8-MOP	Cytotoxicity against human HL60 cells after 24 hrs by trypan blue assay in presence of 0.789 J cm-2 of UVA light Cytotoxicity against human HL60 cells after 24 hrs by trypan blue assay in presence of 0.789 J cm-2 of UVA light	[PMID: 20615713]
HL-60	IC₅₀	5.4 mM Compound: 8-MOP (8-Methoxypsoralen)	In vitro antiproliferative activity against human promyelocytic (HL-60) cells In vitro antiproliferative activity against human promyelocytic (HL-60) cells	[PMID: 10673096]
HL-60	IC₅₀	5.4 μM Compound: 8 -MOP	Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) after exposure to UV light Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) after exposure to UV light	[PMID: 12930143]
HL-60	IC₅₀	5.4 μM Compound: 8-MOP	The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated) The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)	[PMID: 10543884]
HL-60	IC₅₀	5.4 μM Compound: 8-MOP	Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HL-60 cell line Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HL-60 cell line	[PMID: 11965365]
HL-60	IC₅₀	5.4 μM Compound: 8-MOP	Antiproliferative activity against HL60 cells in presence of 0.789 J/cm2 UVA light Antiproliferative activity against HL60 cells in presence of 0.789 J/cm2 UVA light	[PMID: 16821791]
HT-1080	IC₅₀	1.5 μM Compound: 8-MOP	Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	1.9 μM Compound: 8-MOP	Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HT-1080	IC₅₀	2.1 μM Compound: 8-MOP	Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	7.8 μM Compound: 8-MOP	Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	7.8 μM Compound: 8-MOP	Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HT-29	IC₅₀	>100 μM Compound: 6	Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 23746477]
Jurkat	IC₅₀	>20 μM Compound: 8MOP	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 19230658]
Jurkat	IC₅₀	1.2 μM Compound: 8MOP	Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
Jurkat	IC₅₀	1.2 μM Compound: 8-MOP	Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
K562	IC₅₀	>20 μM Compound: 8MOP	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19230658]
L02	IC₅₀	>100 μM Compound: Xanthotoxin	Anti-proliferative activity against human L02 cells after 48 hrs by MTT assay Anti-proliferative activity against human L02 cells after 48 hrs by MTT assay	[PMID: 28947149]
LoVo	IC₅₀	>20 μM Compound: 8MOP	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	0.4 μM Compound: 8-MOP	Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm2 UVA dose Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm2 UVA dose	[PMID: 15837311]
LoVo	IC₅₀	0.7 μM Compound: 8MOP	Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	0.7 μM Compound: 8-MOP	Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
LoVo	IC₅₀	0.7 μM Compound: 8-MOP	Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm2 UVA dose Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm2 UVA dose	[PMID: 15837311]
LoVo	IC₅₀	1.1 μM Compound: 8MOP	Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	1.1 μM Compound: 8-MOP	Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
LoVo	IC₅₀	1.1 μM Compound: 8-MOP	Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm2 UVA dose Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm2 UVA dose	[PMID: 15837311]
MES-SA/Dx5	IC₅₀	3.1 μM Compound: 6	Cytotoxicity against human MES-SA/Dx5 cells after 96 hrs by MTT assay Cytotoxicity against human MES-SA/Dx5 cells after 96 hrs by MTT assay	[PMID: 23746477]
NCTC-2544	IC₅₀	>20 μM Compound: 8MOP	Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay	[PMID: 19230658]
NCTC-2544	IC₅₀	0.9 μM Compound: 8-MOP	Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
NCTC-2544	IC₅₀	5.5 μM Compound: 8MOP	Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
NCTC-2544	IC₅₀	5.5 μM Compound: 8-MOP	Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
PAM212	IC₅₀	>100 μM Compound: 2; 8-MOP	Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 30 mins under dark condition measured after 5 days by coulter counting method Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 30 mins under dark condition measured after 5 days by coulter counting method	[PMID: 30638875]
PAM212	IC₅₀	>100 μM Compound: 2; 8-MOP	Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 5 days under dark condition by coulter counting method Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 5 days under dark condition by coulter counting method	[PMID: 30638875]
PAM212	IC₅₀	0.1 μM Compound: 2; 8-MOP	Phototoxicity against mouse PAM212 cells assessed as cell growth inhibition preincubated for 30 mins followed by 1.28 J/cm2 UV light exposure and measured after 5 days by coulter counting method Phototoxicity against mouse PAM212 cells assessed as cell growth inhibition preincubated for 30 mins followed by 1.28 J/cm2 UV light exposure and measured after 5 days by coulter counting method	[PMID: 30638875]
PANC-1	IC₅₀	83.3 μM Compound: 6	Cytotoxicity against human PANC1 cells after 96 hrs by MTT assay Cytotoxicity against human PANC1 cells after 96 hrs by MTT assay	[PMID: 23746477]
Panel leukemia (Carcinoma cell lines)	IC₅₀	>100 μM Compound: 1	In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture under the dark conditions In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture under the dark conditions	[PMID: 8164263]
Panel leukemia (Carcinoma cell lines)	IC₅₀	100 μM Compound: 1	In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture irradiated at 366 nM In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture irradiated at 366 nM	[PMID: 8164263]
Raji	IC₅₀	490 molar ratio Compound: 7	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells Inhibition of TPA-induced EBV-early antigen activation in human Raji cells	[PMID: 16441065]

In Vivo

Methoxsalen (15mg/kg, i.p, single dose) increases nicotine’s C_max prolongs the plasma nicotine half-life (fourfold increase), decreases its clearance (sixfold decrease), and increases its AUC^[1].
Methoxsalen (15mg/kg, i.p, single dose) enhances the potency of pharmacological effects of oral nicotine (i.e., body temperature and analgesia)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male adult ICR mice^[1]
Dosage:

15 mg/kg
Administration:

Intraperitoneal injection (i.p.), single dose
Result:

Increased nicotine plasma levels were still above 10ng/ml at 6hr.
Induced nicotine’s antinociceptive and hypothermic lasted close to 6 and 24 hr.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 298-81-7
Appearance Solid
Masse moléculaire 216.19
Formule C₁₂H₈O₄
Color White to light yellow
SMILES

O=C1OC(C(C=C1)=C2)=C(OC)C3=C2C=CO3
Synonyms

8-Methoxypsoralen; Xanthotoxin; 8-MOP
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (17)

All Microbiological AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nat Commun

CYP6AE gene cluster knockout in Helicoverpa armigera reveals role in detoxification of phytochemicals and insecticides. [Abstract]

2018 Nov 16;9(1):4820. PMID: 30446639

Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820. [Abstract]

Compared with the SCD strain, LC50 values were significantly decreased to Methoxsalen (xanthotoxin, 4.1-fold) and 2-tridecanone (1.4-fold) in the knockout SCD-d6AE strain.

Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820. [Abstract]

Metabolism of Methoxsalen (xanthotoxin), 2-tridecanone, and indoxacarb by recombinant P450s. CYP6AE subfamily enzymes were from H. armigera and CYP6B1 from Papilio polyxenes. Error bars represent mean values ± SEM (n = 4). Asterisk indicates that no significant metabolism was detected (limits of detection were 0.081, 0.033, and 0.016 pmol/min/pmol P450 for Methoxsalen (xanthotoxin), 2-tridecanone, and indoxacarb, respectively).

Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820. [Abstract]

The results showed that the CYP6AE19 and CYP6AE20 transcripts (>1000-fold induction in midgut and >100-fold induction in fat body) are very strongly induced by Methoxsalen (xanthotoxin). Furthermore, CYP6AE14 transcripts are induced in midgut (40-fold) after dietary exposure to gossypol.
Proc Natl Acad Sci U S A

Divergent amplifications of CYP9A cytochrome P450 genes provide two noctuid pests with differential protection against xenobiotics. [Abstract]

2023 Sep 12;120(37):e2308685120. PMID: 37669374
Chemosphere

A proposed "steric-like effect" for the slowdown of enrofloxacin antibiotic metabolism by ciprofloxacin, and its mechanism. [Abstract]

2021 Dec:284:131347. PMID: 34323809
Br J Pharmacol

Transient Receptor Potential channels, TRPV1 and TRPA1 in melanocytes synergize UV-dependent and UV-independent melanogenesis. [Abstract]

2021 Dec;178(23):4646-4662. PMID: 34363226
Anal Chem

A Computational Integration Strategy Driven by Chemical Similarity Uncovers Comprehensive Metabolic Profiles of Small Bioactive Peptides via UHPLC-HRMS for Doping Control. [Abstract]

2025 Nov 18;97(45):25158-25167. PMID: 41202118
Clin Chem

Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records. [Abstract]

2019 Dec;65(12):1522-1531. PMID: 31578215

Methoxsalen purchased from MedChemExpress. Usage Cited in: Clin Chem. 2019 Dec;65(12):1522-1531. [Abstract]

Top-ranked ingredients associated with false positives on the amphetamines and buprenorphine screens.
J Ethnopharmacol

Discovery of bakuchiol as an AIM2 inflammasome activator and cause of hepatotoxicity. [Abstract]

2022 Nov 15:298:115593. PMID: 35973629
Sci Rep

Dermal papilla cells-conditioned medium attenuates oxidative stress-induced senescence via ferroptosis inhibition. [Abstract]

2025 Jul 9;15(1):24789. PMID: 40634437
Insect Biochem Mol Biol

Single amino acid variations drive functional divergence of cytochrome P450s in Helicoverpa species. [Abstract]

2022 Jul:146:103796. PMID: 35636594

Methoxsalen purchased from MedChemExpress. Usage Cited in: Insect Biochem Mol Biol. 2022 Jul:146:103796. [Abstract]

Qualitative enzyme activities to Methoxsalen (xanthotoxin) with six recombinant mutants.
Insect Biochem Mol Biol

Involvement of CYP2 and mitochondrial clan P450s of Helicoverpa armigera in xenobiotic metabolism. [Abstract]

2022 Jan:140:103696. PMID: 34800643
Food Chem Toxicol

The "steric-like" inhibitory effect and mechanism of doxycycline on florfenicol metabolism: Interaction risk. [Abstract]

2022 Nov:169:113431. PMID: 36116547
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
J Clin Apher

Suppressive CD8+ T-Cells Are Key Cellular Mediators of Extracorporeal Photopheresis. [Abstract]

2026 Feb;41(1):e70094. PMID: 41653030
Journal of Dermatologic Science and Cosmetic Technology

2025 Jun.
bioRxiv

2023 Jun 15.
Research Square Preprint

2021 Aug.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (231.28 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.6256 mL

23.1278 mL

46.2556 mL

5 mM

0.9251 mL

4.6256 mL

9.2511 mL

10 mM

0.4626 mL

2.3128 mL

4.6256 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Alsharari SD, et al. Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor. Nicotine Tob Res. 2014 Jan;16(1):18-25. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.6256 mL	23.1278 mL	46.2556 mL	115.6390 mL
	5 mM	0.9251 mL	4.6256 mL	9.2511 mL	23.1278 mL
	10 mM	0.4626 mL	2.3128 mL	4.6256 mL	11.5639 mL
	15 mM	0.3084 mL	1.5419 mL	3.0837 mL	7.7093 mL
	20 mM	0.2313 mL	1.1564 mL	2.3128 mL	5.7820 mL
	25 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6256 mL
	30 mM	0.1542 mL	0.7709 mL	1.5419 mL	3.8546 mL
	40 mM	0.1156 mL	0.5782 mL	1.1564 mL	2.8910 mL
	50 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	60 mM	0.0771 mL	0.3855 mL	0.7709 mL	1.9273 mL
	80 mM	0.0578 mL	0.2891 mL	0.5782 mL	1.4455 mL
	100 mM	0.0463 mL	0.2313 mL	0.4626 mL	1.1564 mL

Keywords

Methoxsalen

17 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Methoxsalen

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Food-Sourced Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Hematopathy Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Biotoxin Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Methoxsalen

Voir tous les produits spécifiques à Isoform Cytochrome P450

Activité biologique

Chemical Information

Publications (17)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Methoxsalen Related Classifications

HY-30151 Related Classifications